博彩导航

博彩导航
宁波大学 主任信箱 ENGLISH
科学研究
杏林讲坛第102讲---药学篇:Role of Toxicology in New Drug Development (NDD)
2024-03-20  
 

报告题目:Role of Toxicology in New Drug Development (NDD)

时间:2024年3月25日(周一)10:00-11:30

地点:博彩导航 王长来楼多功能厅

主讲人:Charles C. Zhang

个人简介:

      Dr. Charles C. Zhang currently serves as the Toxicology Leader at the Bill & Melinda Gates Foundation (BMGF)’s Medical Research Institute (Gates MRI), where he spearheads nonclinical safety assessment within multidisciplinary development teams. As the toxicology subject matter expert for BMGF, Charles focuses on programs dedicated to alleviating the burden of tuberculosis (TB), malaria, diarrheal diseases, and maternal, newborn, and child illnesses in low-and-middle-income countries (LMICs).

    Charles earned his Ph.D. in Pharmacology from the University of Arkansas for Medical Sciences (Little Rock, AR, USA) in 2000. He holds certification (DABT) from the American Board of Toxicology (2005, 2010, 2015, 2020) in general toxicology and is currently pursuing an EMBA at the Kellogg School of Management at Northwestern University (Chicago, IL, USA), with an expected completion date in 2025.

          As a seasoned entrepreneur and translational medicine expert, Charles boasts a 23-year track record leading new drug development endeavors in the biopharmaceutical industry in the USA. His achievements include authoring 2 NDA (1 as the nonclinical biology lea), 1 PMA (medical device), 8 INDs and 3 CTAs for worldwide submissions.

科学研究
通知公告 科研项目 科研成果 科研平台 科研团队 学术交流 地方服务 制度流程 相关下载
杏林讲坛第102讲---药学篇:Role of Toxicology in New Drug Development (NDD)
编辑:发布时间:2024-03-20

报告题目:Role of Toxicology in New Drug Development (NDD)

时间:2024年3月25日(周一)10:00-11:30

地点:博彩导航 王长来楼多功能厅

主讲人:Charles C. Zhang

个人简介:

      Dr. Charles C. Zhang currently serves as the Toxicology Leader at the Bill & Melinda Gates Foundation (BMGF)’s Medical Research Institute (Gates MRI), where he spearheads nonclinical safety assessment within multidisciplinary development teams. As the toxicology subject matter expert for BMGF, Charles focuses on programs dedicated to alleviating the burden of tuberculosis (TB), malaria, diarrheal diseases, and maternal, newborn, and child illnesses in low-and-middle-income countries (LMICs).

    Charles earned his Ph.D. in Pharmacology from the University of Arkansas for Medical Sciences (Little Rock, AR, USA) in 2000. He holds certification (DABT) from the American Board of Toxicology (2005, 2010, 2015, 2020) in general toxicology and is currently pursuing an EMBA at the Kellogg School of Management at Northwestern University (Chicago, IL, USA), with an expected completion date in 2025.

          As a seasoned entrepreneur and translational medicine expert, Charles boasts a 23-year track record leading new drug development endeavors in the biopharmaceutical industry in the USA. His achievements include authoring 2 NDA (1 as the nonclinical biology lea), 1 PMA (medical device), 8 INDs and 3 CTAs for worldwide submissions.

快速入口  SHORTCUT